Table 1.
NaCl | Coversin + anti-CD14 | Untreated vs. treated | ||
---|---|---|---|---|
Changea (Meanc) | Change (Mean) | Difference (Mean diff.) | P-valueb (P-valued) | |
Hemoglobin (g/dL) | 2.2 ± 0.21 (10) | 2.2 ± 0.28 (10) | 0.0 ± 0.35 (0) | 0.87 (0.42) |
Leukocytes (109/L) | 5.7 ± 0.89 (5.8) | 5.8 ± 0.78 (5.9) | 0.1 ± 1.38 (0.1) | >0.99 (>0.99) |
Thrombocytes (109/L) | 205 ± 37 (296) | 198 ± 33 (230) | 7 ± 37 (66) | 0.78 (0.30) |
Creatinine (μmol/L) | 64 ± 8.9 (79) | 73 ± 6.5 (88) | 9 ± 7.2 (9) | 0.15 (0.18) |
ALAT (U/L) | 18 ± 8.2 (43) | 14 ± 2.3 (39) | 4 ± 9.3 (4) | 0.41 (0.91) |
ASAT (U/L) | 99 ± 21 (54) | 94 ± 16 (52) | 5 ± 30 (2) | 0.81 (0.85) |
Creatinine kinase (U/L) | 305 ± 57 (448) | 434 ± 69 (513) | 129 ± 63 (65) | 0.13 (0.30) |
Albumin (g/L) | 8.1 ± 0.6 (24) | 10 ± 0.8 (23) | 1.9 ± 1.2 (1) | 0.20 (0.18) |
Total protein (g/L) | 12 ± 1.1 (37) | 15 ± 1.5 (34) | 3 ± 2.0 (3) | 0.27 (0.02*) |
aChange represents the difference between maximum and minimum values ± SEM
bThe difference in change in the two groups was compared using Wilcoxon matched-pairs signed rank test
cMean level throughout the experiment
dThe difference in means (mean diff.) in the two groups was also compared using the Wilcoxon matched-pairs signed rank test. * P < 0.05 was considered significant